Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Titles
NEW
 Top 50 Non-Healthcare Titles
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Generic Central Nervous System Drugs Global Market Report 2025
Request Sample Buy Now
Global Generic Central Nervous System Drugs Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Generic Central Nervous System Drugs Global Market Report 2025

By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types), By Drug Classification (Branded Drugs, Generic Drugs), By Disease (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation, Other Route Of Administrations), By Mode Of Purchase (Over-the-counter drugs, Prescription-Based Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Generic Central Nervous System Drugs Market Overview

• Generic Central Nervous System Drugs market size has reached to $88.43 billion in 2024

• Expected to grow to $123.41 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%

• Growth Driver: Rising Incidence Of Mental Health Disorders Fuels Growth In The Generic Central Nervous System (CNS) Drug Market

• Market Trend: Generic CNS Drugs Market Embraces Biosimilar Development For Enhanced Treatment Options

• North America was the largest region in 2024.

What Is Covered Under Generic Central Nervous System Drugs Market?

Generic central nervous system (CNS) drugs refer to the drugs that have an impact on the central nervous system agents (CNS) by slowing down brain activity. They are used to treat seizures, anxiety, panic attacks, and insomnia.

The major types of generic central nervous system drugs are anti-psychotics, analgesics, anti-parkinson drugs, anesthetics, anti-epileptics, anti-depressants, and others. Antipsychotics, also known as neuroleptics, are a class of medications primarily used to manage symptoms associated with psychotic disorders, such as schizophrenia and bipolar disorder. The drug classification is branded drugs and generic drugs and the route of administration includes oral, intravenous, intranasal or inhalation, and other various diseases such as neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, and CNS cancer. The mode of purchase includes over-the-counter drugs, and prescription-based drugs and is distributed by various channels such as hospital pharmacies, retail pharmacies, and others.

Generic Central Nervous System Drugs Market 2025 - 2034

What Is The Generic Central Nervous System Drugs Market Size 2025 And Growth Rate?

The generic central nervous system drugs market size has grown strongly in recent years. It will grow from $88.43 billion in 2024 to $93.53 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to from increasing number of surgeries, strong growth in emerging markets, an increase in pharmaceutical R&D, geriatric population, and increased healthcare expenditure.

What Is The Generic Central Nervous System Drugs Market Growth Forecast?

The generic central nervous system drugs market size is expected to see strong growth in the next few years. It will grow to $123.41 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growing government initiatives for mental health awareness, a rise in healthcare expenditure, an increasing geriatric population, and a strong pipeline of drugs. Major trends in the forecast period include investing in wearable technology, biomarkers in CNS development, modifying existing drugs, investing in drug pipeline, using 3D printing for drug manufacturing, and focusing on establishing collaborations with research institutions and established companies.

The forecast of 7.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs could disrupt U.S. mental health treatment by increasing prices of selective serotonin reuptake inhibitors tablets and neuropsychiatric rating scale instruments sourced from Israel and Ireland, exacerbating depression management costs and psychiatric care burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Generic Central Nervous System Drugs Market Segmented?

1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types

2) By Drug Classification: Branded Drugs, Generic Drugs

3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer

4) By Route Of Administration: Oral, Intravenous, Intranasal Or Inhalation, Other Route Of Administrations

5) By Mode Of Purchase: Over-The-counter drugs, Prescription-Based Drugs

6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Multiple Sclerosis (MS): Interferons, Glatiramer Acetate, Sphingosine-1 Phosphate Receptor Modulators, Monoclonal Antibodies

2) By Anti-Psychotic: Atypical Antipsychotics, Typical Antipsychotics

3) By Analgesics: Non-Opioid Analgesics, Opioid Analgesics, Combination Analgesics

4) By Anti-Parkinson Drugs: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

5) By Anesthetics: General Anesthetics, Local Anesthetics

6) By Anti-Epileptics: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Mechanisms

7) By Anti-Depressants: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

8) By Other Types: Cognitive Enhancers, Anxiolytics, Sleep Aids

What Is Driving The Generic Central Nervous System Drugs Market? Rising Incidence Of Mental Health Disorders Fuels Growth In The Generic Central Nervous System (CNS) Drug Market

The increasing incidence of mental health disorders is expected to propel the growth of the generic central nervous system (CNS) drug market going forward. A mental health disorder is a clinically substantial impairment in a person's cognition, emotional regulation, or conduct. It is usually linked to distress or functional impairment in key areas. Generic central nervous system (CNS) drugs play a crucial role in the management of mental health disorders by providing affordable and accessible treatment options. For instance, in November 2022, according to the Health and Social Care Information Centre, a UK-based federal body that offers content, data, and computer systems for experts, physicians, and controllers in the social and healthcare sectors, the proportion of 17- to 19-year-olds with a suspected mental disorder grew from 17.4% in 2021 to 25.7% in 2022. Therefore, the increasing incidence of mental health disorders is driving the generic central nervous system (CNS) drug market.

What Is Driving The Generic Central Nervous System Drugs Market? Surging Healthcare Expenditure Drives Expansion Of The Generic Central Nervous System (CNS) Drug Market

The rising healthcare expenditure drives the growth of the generic central nervous system (CNS) drug market in the forecast period. Healthcare expenditure refers to the total amount of resources spent on healthcare goods and services within a specific period. The generic central nervous system (CNS) drug industry benefits from healthcare spending in several ways, including increased accessibility, affordability, and innovation in the drugs used to treat mental health conditions. For instance, according to the Centers for Medicare & Medicaid Services, a US-based federal healthcare agency, average National Health Expenditures (NHE) growth (5.4%) is projected to exceed average GDP growth (4.6%) between 2022 and 2031, resulting in an increase in the health-spending share of GDP from 18.3% in 2021 to 19.6% in 2031. Additionally, in April 2022, according to a report published by the National Association of Chronic Disease Directors (NACDD), a US-based non-profit public health organization dedicated to chronic disease programs, almost 60 percent of adult Americans have at least one chronic disease, and approximately 40% of American adults have multiple chronic conditions (MCC), and this is expected to cost the US economy $2 trillion annually, or $8,600 per person by 2030. Thus, the rising healthcare expenditure will propel the growth of the generic central nervous system (CNS) drug market.

Who Are The Major Players In The Global Generic Central Nervous System Drugs Market?

Major companies operating in the generic central nervous system drugs market include Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, União Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram

What Are The Key Trends Of The Global Generic Central Nervous System Drugs Market? Generic CNS Drugs Market Embraces Biosimilar Development For Enhanced Treatment Options

Major companies operating in the generic central nervous system drugs market are focused on developing biosimilars for central nervous system (CNS) conditions. The development and approval of biosimilars for certain biologic drugs used in CNS disorders are becoming a trend, offering more cost-effective alternatives to branded biologics. For instance, in October 2023, Sandoz a Switzerland-based pharmaceutical company launched natalizumab-sztn, the first biosimilar to treat relapsing forms of multiple sclerosis (MS). This includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. MS is an autoimmune disease that affects the central nervous system and is chronic and progressive. The majority of disease-affected individuals go through periods of remission and relapse, which negatively impacts their quality of life. The treatment will be contraindicated in patients with progressive multifocal leukoencephalopathy (PML) and in those who previously had PML.

Need data on a specific region in this market?
Request Customisation

What Are Latest Mergers And Acquisitions In The Generic Central Nervous System Drugs Market? Avenue Therapeutics Expands CNS Portfolio With Acquisition Of Baergic Bio

In November 2022, Avenue Therapeutics, a US-based specialty pharmaceutical company, acquired Baergic Bio for an undisclosed amount. This acquisition makes Avenue a pioneer in the creation of medications that address unmet medical needs in the CNS field. Baergic Bio is a US-based biopharmaceutical company dedicated to the creation and marketing of cutting-edge therapies for the management of CNS (central nervous system) diseases.

Regional Outlook For The Global Generic Central Nervous System Drugs Market

North America was the largest region in the generic central nervous system drugs market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

What Defines the Generic Central Nervous System Drugs Market?

The generic central nervous system drugs market consists of sales of sedatives, tranquilizers, and hypnotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Generic Central Nervous System Drugs Industry?

The generic central nervous system drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the generic central nervous system drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Generic Central Nervous System Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $93.53 billion
Revenue Forecast In 2034 $123.41 billion
Growth Rate CAGR of 7.2% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
4) By Route Of Administration: Oral, Intravenous, Intranasal Or Inhalation, Other Route Of Administrations
5) By Mode Of Purchase: Over-The-counter drugs, Prescription-Based Drugs 6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels Subsegments: 1) By Multiple Sclerosis (MS): Interferons, Glatiramer Acetate, Sphingosine-1 Phosphate Receptor Modulators, Monoclonal Antibodies
2) By Anti-Psychotic: Atypical Antipsychotics, Typical Antipsychotics
3) By Analgesics: Non-Opioid Analgesics, Opioid Analgesics, Combination Analgesics
4) By Anti-Parkinson Drugs: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
5) By Anesthetics: General Anesthetics, Local Anesthetics 6) By Anti-Epileptics: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Mechanisms 7) By Anti-Depressants: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants 8) By Other Types: Cognitive Enhancers, Anxiolytics, Sleep Aids
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, União Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Generic Central Nervous System Drugs Market Characteristics

3. Generic Central Nervous System Drugs Market Trends And Strategies

4. Generic Central Nervous System Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Generic Central Nervous System Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Generic Central Nervous System Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Generic Central Nervous System Drugs Market Growth Rate Analysis

5.4. Global Generic Central Nervous System Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Generic Central Nervous System Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Generic Central Nervous System Drugs Total Addressable Market (TAM)

6. Generic Central Nervous System Drugs Market Segmentation

6.1. Global Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Multiple Sclerosis (MS)

Anti-Psychotic

Analgesics

Anti-Parkinson Drugs

Anesthetics

Anti-Epileptics

Anti-Depressants

Other Types

6.2. Global Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Branded Drugs

Generic Drugs

6.3. Global Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Neurovascular Diseases

CNS Trauma

Mental Health

Neurodegenerative Diseases

Infectious Diseases

CNS Cancer

6.4. Global Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Intravenous

Intranasal/ Inhalation

Other Route Of Administrations

6.5. Global Generic Central Nervous System Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Over-the-counter drugs

Prescription-Based Drugs

6.6. Global Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Other Distribution Channels

6.7. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Multiple Sclerosis (MS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Interferons

Glatiramer Acetate

Sphingosine-1 Phosphate Receptor Modulators

Monoclonal Antibodies

6.8. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Psychotic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Atypical Antipsychotics

Typical Antipsychotics

6.9. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Non-Opioid Analgesics

Opioid Analgesics

Combination Analgesics

6.10. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Parkinson Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Dopamine Agonists

MAO-B Inhibitors

COMT Inhibitors

Anticholinergics

6.11. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anesthetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

General Anesthetics

Local Anesthetics

6.12. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Epileptics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Sodium Channel Blockers

GABA Enhancers

Glutamate Modulators

Other Mechanisms

6.13. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Depressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Selective Serotonin Reuptake Inhibitors (SSRIs)

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Tricyclic Antidepressants (TCAs)

Monoamine Oxidase Inhibitors (MAOIs)

Atypical Antidepressants

6.14. Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Cognitive Enhancers

Anxiolytics

Sleep Aids

7. Generic Central Nervous System Drugs Market Regional And Country Analysis

7.1. Global Generic Central Nervous System Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Generic Central Nervous System Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Generic Central Nervous System Drugs Market

8.1. Asia-Pacific Generic Central Nervous System Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Generic Central Nervous System Drugs Market

9.1. China Generic Central Nervous System Drugs Market Overview

9.2. China Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Generic Central Nervous System Drugs Market

10.1. India Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Generic Central Nervous System Drugs Market

11.1. Japan Generic Central Nervous System Drugs Market Overview

11.2. Japan Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Generic Central Nervous System Drugs Market

12.1. Australia Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Generic Central Nervous System Drugs Market

13.1. Indonesia Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Generic Central Nervous System Drugs Market

14.1. South Korea Generic Central Nervous System Drugs Market Overview

14.2. South Korea Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Generic Central Nervous System Drugs Market

15.1. Western Europe Generic Central Nervous System Drugs Market Overview

15.2. Western Europe Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Generic Central Nervous System Drugs Market

16.1. UK Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Generic Central Nervous System Drugs Market

17.1. Germany Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Generic Central Nervous System Drugs Market

18.1. France Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Generic Central Nervous System Drugs Market

19.1. Italy Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Generic Central Nervous System Drugs Market

20.1. Spain Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Generic Central Nervous System Drugs Market

21.1. Eastern Europe Generic Central Nervous System Drugs Market Overview

21.2. Eastern Europe Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Generic Central Nervous System Drugs Market

22.1. Russia Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Generic Central Nervous System Drugs Market

23.1. North America Generic Central Nervous System Drugs Market Overview

23.2. North America Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Generic Central Nervous System Drugs Market

24.1. USA Generic Central Nervous System Drugs Market Overview

24.2. USA Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Generic Central Nervous System Drugs Market

25.1. Canada Generic Central Nervous System Drugs Market Overview

25.2. Canada Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Generic Central Nervous System Drugs Market

26.1. South America Generic Central Nervous System Drugs Market Overview

26.2. South America Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Generic Central Nervous System Drugs Market

27.1. Brazil Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Generic Central Nervous System Drugs Market

28.1. Middle East Generic Central Nervous System Drugs Market Overview

28.2. Middle East Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Generic Central Nervous System Drugs Market

29.1. Africa Generic Central Nervous System Drugs Market Overview

29.2. Africa Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Generic Central Nervous System Drugs Market Competitive Landscape And Company Profiles

30.1. Generic Central Nervous System Drugs Market Competitive Landscape

30.2. Generic Central Nervous System Drugs Market Company Profiles

30.2.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. UCB Overview, Products and Services, Strategy and Financial Analysis

31. Generic Central Nervous System Drugs Market Other Major And Innovative Companies

31.1. Sanofi

31.2. Pfizer Inc.

31.3. Merck KGaA

31.4. Sumitomo Dainippon Pharma

31.5. AbbVie

31.6. Recipharm AB

31.7. Neuraxpharm

31.8. Sun Pharmaceutical limited

31.9. Ranbaxy Laboratories

31.10. Merz Pharma GmbH & Co. KGaAare

31.11. AstraZeneca

31.12. Apotex

31.13. Gilead Sciences

31.14. Bayer

31.15. GlaxoSmithKline

32. Global Generic Central Nervous System Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Generic Central Nervous System Drugs Market

34. Recent Developments In The Generic Central Nervous System Drugs Market

35. Generic Central Nervous System Drugs Market High Potential Countries, Segments and Strategies

35.1 Generic Central Nervous System Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Generic Central Nervous System Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Generic Central Nervous System Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Generic Central Nervous System Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Multiple Sclerosis (MS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Psychotic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Parkinson Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anesthetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Epileptics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Depressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Global Generic Central Nervous System Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: Global Generic Central Nervous System Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: Asia-Pacific, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Asia-Pacific, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Asia-Pacific, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: China, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: China, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: China, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: India, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: India, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: India, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Japan, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Japan, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Japan, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Australia, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Australia, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Australia, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Indonesia, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Indonesia, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Indonesia, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: South Korea, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: South Korea, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: South Korea, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Western Europe, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Western Europe, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Western Europe, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: UK, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: UK, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: UK, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Germany, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Germany, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Germany, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: France, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: France, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: France, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Italy, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Italy, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Italy, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Spain, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Spain, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Spain, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Eastern Europe, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Eastern Europe, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: Eastern Europe, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: Russia, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Russia, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Russia, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: North America, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: North America, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: North America, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: USA, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: USA, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: USA, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Canada, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Canada, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Canada, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: South America, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: South America, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: South America, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Brazil, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Brazil, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Brazil, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Middle East, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Middle East, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Middle East, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 82: Africa, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 83: Africa, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 84: Africa, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 85: Biogen Inc. Financial Performance
  • Table 86: Johnson & Johnson Financial Performance
  • Table 87: Hoffmann-La Roche Ltd Financial Performance
  • Table 88: Novartis AG Financial Performance
  • Table 89: UCB Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Generic Central Nervous System Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Multiple Sclerosis (MS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Psychotic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Parkinson Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anesthetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Epileptics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Anti-Depressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Global Generic Central Nervous System Drugs Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Global Generic Central Nervous System Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: Global Generic Central Nervous System Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: Asia-Pacific, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Asia-Pacific, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Asia-Pacific, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: China, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: China, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: China, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: India, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: India, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: India, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Japan, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Japan, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Japan, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Australia, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Australia, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Australia, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Indonesia, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Indonesia, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Indonesia, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: South Korea, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: South Korea, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: South Korea, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Western Europe, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Western Europe, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Western Europe, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: UK, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: UK, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: UK, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Germany, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Germany, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Germany, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: France, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: France, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: France, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Italy, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Italy, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Italy, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Spain, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Spain, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Spain, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Eastern Europe, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Eastern Europe, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: Eastern Europe, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: Russia, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Russia, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Russia, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: North America, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: North America, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: North America, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: USA, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: USA, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: USA, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Canada, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Canada, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Canada, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: South America, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: South America, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: South America, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Brazil, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Brazil, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Brazil, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Middle East, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Middle East, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Middle East, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 82: Africa, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 83: Africa, Generic Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 84: Africa, Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 85: Biogen Inc. Financial Performance
  • Figure 86: Johnson & Johnson Financial Performance
  • Figure 87: Hoffmann-La Roche Ltd Financial Performance
  • Figure 88: Novartis AG Financial Performance
  • Figure 89: UCB Financial Performance

Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Read More About Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Read More About Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Read More About Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

Read More About Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Ho...

View Report

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By ...

View Report

Pharmaceutical Drugs Market 2024 – By Type (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorde...

View Report

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

View Report

Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospi...

View Report

Respiratory Diseases Drugs Global Market Report 2022 – By Type (Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Adm...

View Report

Gastrointestinal Drugs Global Market Report 2022 – By Type (Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals), By Distribution Channel (Hospital Pharmacies, Retai...

View Report

Hematology Drugs Global Market Report 2022 – By Type (Blood Products, Anemia And Other Blood Disorder Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administrat...

View Report

Frequently Asked Questions

Generic central nervous system (CNS) drugs refer to the drugs that have an impact on the central nervous system agents (CNS) by slowing down brain activity. They are used to treat seizures, anxiety, panic attacks, and insomnia. For further insights on this market, request a sample here

The market major growth driver - Rising Incidence Of Mental Health Disorders Fuels Growth In The Generic Central Nervous System (CNS) Drug Market. For further insights on this market, request a sample here

The generic central nervous system drugs market size has grown strongly in recent years. It will grow from $88.43 billion in 2024 to $93.53 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to from increasing number of surgeries, strong growth in emerging markets, an increase in pharmaceutical R&D, geriatric population, and increased healthcare expenditure. The generic central nervous system drugs market size is expected to see strong growth in the next few years. It will grow to " $123.41 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growing government initiatives for mental health awareness, a rise in healthcare expenditure, an increasing geriatric population, and a strong pipeline of drugs. Major trends in the forecast period include investing in wearable technology, biomarkers in CNS development, modifying existing drugs, investing in drug pipeline, using 3D printing for drug manufacturing, and focusing on establishing collaborations with research institutions and established companies. For further insights on this market, request a sample here

The generic central nervous system drugs market covered in this report is segmented –
1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
4) By Route Of Administration: Oral, Intravenous, Intranasal Or Inhalation, Other Route Of Administrations
5) By Mode Of Purchase: Over-The-counter drugs, Prescription-Based Drugs
6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels Subsegments:
1) By Multiple Sclerosis (MS): Interferons, Glatiramer Acetate, Sphingosine-1 Phosphate Receptor Modulators, Monoclonal Antibodies
2) By Anti-Psychotic: Atypical Antipsychotics, Typical Antipsychotics
3) By Analgesics: Non-Opioid Analgesics, Opioid Analgesics, Combination Analgesics
4) By Anti-Parkinson Drugs: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
5) By Anesthetics: General Anesthetics, Local Anesthetics
6) By Anti-Epileptics: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Mechanisms
7) By Anti-Depressants: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants
8) By Other Types: Cognitive Enhancers, Anxiolytics, Sleep Aids For further insights on this market, request a sample here

North America was the largest region in the generic central nervous system drugs market in 2024. The regions covered in the generic central nervous system drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the generic central nervous system drugs market include Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, União Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram . For further insights on this market, request a sample here.

Major trends in this market include Generic CNS Drugs Market Embraces Biosimilar Development For Enhanced Treatment Options. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Generic Central Nervous System Drugs Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top